ML-007C-MA Phase 2 trial results released
MapLight Therapeutics reported topline data from its Phase 2 ZEPHYR trial evaluating its schizophrenia candidate ML-007C-MA. The data release is critical for the company's clinical development plans and potential market position in the psychiatric disorders treatment space.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day